Neurology Alert – January 1, 2020
January 1, 2020
View Issues
-
Significance of Brain Microbleeds After Traumatic Brain Injury
Traumatic microbleeds are common in patients with any severity of traumatic brain injury and may be a useful biomarker to predict clinical outcomes.
-
Neuropathology and Dementia in Football Players With CTE
The authors of a cross-sectional study involving analysis of data from the ongoing Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) study found that dementia is likely a result of neuropathologic changes associated with repetitive head injury as well as non-head trauma-associated vascular pathologic changes in patients with chronic traumatic encephalopathy.
-
Fluctuating Cognition: An Often-Neglected Feature of Lewy Body Dementias
Clinical identification of fluctuating cognition is challenging. A better understanding of potential etiological mechanisms can allow for optimization of clinical assessment tools and targeted therapeutic approaches.
-
Submentalis REM Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy
Objective findings during polysomnography (REM sleep without atonia), as diagnosed with submentalis EMG recordings, may be a biomarker for synucleinopathies, such as Parkinson’s disease and multiple system atrophy.
-
Stereotactic Radiosurgery for the Treatment of Cerebral Cavernous Malformations
In this comprehensive review of studies comparing treatments for cerebral cavernous malformations, there were no randomized or blinded outcome trials, and the most effective treatment remains uncertain.
-
Does a Repeat Course of IVIg Help in Severe Guillain-Barré Syndrome?
In an open-label, non-randomized clinical trial using a second course of intravenous immunoglobulin (IVIg) to treat patients with Guillain-Barré syndrome, no benefit was observed. A single course of 2 g/kg of IVIg should be administered. No additional treatment is helpful.